Revance Therapeutics, Inc. produces biopharmaceutical products. The Company develops drug delivery and treatments for dermatology and aesthetic medicine. Revance Therapeutics serves patients and doctors throughout the United States.

Current Report (Form 8-K | Period ending 2024-12-11)

SC14D9C | Written communication by the subject company relating to a third party tender offer

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Revance Therapeutics (RVNC US)

Current Report (Form 8-K | Period ending 2024-12-11)

SC14D9C | Written communication by the subject company relating to a third party tender offer

Current Report (Form 8-K | Period ending 2024-12-07)

Current Report (Form 8-K | Period ending 2024-12-05)

Current Report (Form 8-K | Period ending 2024-12-03)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)